SciMatic
Journals
Thesis Rep
Docs
Products
SciMatic.net
Journament
Journal Manager
Subjects
Thesis
ImProofer
Research Groups
Letter Pad
Conferences
Services
About
SciMatic
Team
Earn With Us
Join Us
Contact Us
EN
English
Türkçe
Español
Português
Pусский
Filipino
Tiếng Việt
हिन्दी
العربية
বাংলা
Deutsch
中文
Login
Keyword Connections
neutropenia / chemically induced
Journals
0
No Journal Connected
Research Groups
0
No Research Group Connected
Bibliographies
11
1
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america
2
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America
3
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
4
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
5
A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia
6
Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?
7
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee
8
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)
9
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
10
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
11
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study